| |
How is your lab navigating complex NGS workflows? In this webinar, hear subject matter experts explore how a lab informatics solution with out-of-the-box NGS capabilities delivers real value. View Now. 
|
|
Today’s Big NewsSep 14, 2023 |
| By Gabrielle Masson Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two AstraZeneca dumped last year. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor Sanofi has handed First Wave BioPharma a chance to reposition a long-dormant molecule. The biotech is paying a “modest” upfront fee for capeserod as part of a deal that gives Sanofi the right of first refusal to buy the asset back. |
By Nick Paul Taylor AbbVie has punctured Harpoon Therapeutics’ dream of a $200 million payday. Needing to pay the sum to take up its option on the anti-BCMA T-cell engager HPN217, AbbVie has opted against moving deeper into a space that is already congested with candidates including its own rival bispecific. |
Sponsored by IQVIA With IQVIA’s clinical trial solutions and flexible site support strategies, decentralized trial elementss are being leveraged to enhance patient- centered care as well as support sites through hands- on enablement and implementation of DCT platforms these services. |
By Max Bayer Generate Biomedicines has corralled another nine-digit financing, raising $273 million in new funds. The money will go toward expanding a pipeline of infectious disease, immunology and oncology assets. |
By James Waldron After a summer of stasis, Hemogenyx Pharmaceuticals is one step closer to finally getting its CAR-T therapy into the clinic after the FDA accepted its plan to get a clinical hold lifted. |
By Helen Floersh What if the COVID-19 vaccine could be a simple drop under the tongue instead of a shot in the arm? That's the result researchers from Japan’s Intelligence & Technology Lab Inc. and the Biomedical Institute of NPO Primate Agora are hoping for. |
By Fraiser Kansteiner J&J is uniting its medtech and pharmaceutical arms so that they will be “more connected to the Johnson & Johnson brand," the company said. Over time, Janssen is slated to become Johnson & Johnson Innovate Medicine, while the company’s medical technology segment will continue to run with the J&J MedTech moniker. |
By Kevin Dunleavy For decades, hundreds of oral decongestant products containing phenylephrine have been available in the United States over the counter. But on Tuesday, an FDA advisory committee agreed by a 16-0 vote that the ingredient does not work. |
By Joseph Keenan Canadian CRO Cirion Biopharma was acquired by Cerba HealthCare in a deal that expands the French clinical trial lab and diagnostics provider’s offerings and geographic reach. |
By Fraiser Kansteiner Efforts from regulators and manufacturers have brought the U.S. supply of cisplatin back to nearly 100% of pre-shortage levels, according to the White House. The moves are “greatly alleviating the shortages of carboplatin,” too, the White House said. |
By Frank Diamond The Blue Cross Blue Shield Association today released an issue brief that blames provider consolidation for higher costs for care at hospitals. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
